Comparative Activity of Carbapenem Antibiotics Against Gram-Negative Carbapenemase Producers of Different Groups
- 15 April 2022
- journal article
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 67 (1-2), 9-15
- https://doi.org/10.37489/0235-2990-2022-67-1-2-9-15
Abstract
The rapid spread of gram-negative bacteria resistance to carbapenems due to the production of carbapenemases requires new treatment options. The activity of carbapenem antibiotic biapenem, recently registered in Russia, against producers of various carbapenemases was studied in comparison with other antibiotics of this group. Among NDM-type carbapenemase producers, 77.8% demonstrated clinical susceptibility to biapenem; 50.3% and 21.1% of isolates were susceptible to meropenem and imipenem, respectively. Among the producers of OXA-48-type carbapenemases, 82,6%, 60,9%, and 65,2% of isolates demonstrated susceptibility to biapenem, imipenem, and meropenem, respectively.Producers of KPC-type carbapenemases were 100% resistant to all carbapenems. The introduction of biapenem will significantly expand the possibilities of treating severe infections caused by carbapenemase producers.Keywords
This publication has 17 references indexed in Scilit:
- Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infectionJournal of Antimicrobial Chemotherapy, 2017
- Activity of biapenem (RPX2003) combined with the boronate -lactamase inhibitor RPX7009 against carbapenem-resistant EnterobacteriaceaeJournal of Antimicrobial Chemotherapy, 2013
- Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor CombinationDrugs, 2013
- “Stormy waters ahead”: global emergence of carbapenemasesFrontiers in Microbiology, 2013
- Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. with carbapenemases, including NDM enzymesJournal of Antimicrobial Chemotherapy, 2012
- Comparative Review of the CarbapenemsDrugs, 2007
- Metallo-β-Lactamases: the Quiet before the Storm?Clinical Microbiology Reviews, 2005
- Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysisJournal of Infection and Chemotherapy, 2004
- In vitro activity of three carbapenem antibiotics comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwideDiagnostic Microbiology and Infectious Disease, 1993
- The structure of β-lactamasesPhilosophical Transactions of the Royal Society of London. B, Biological Sciences, 1980